Renaissance Capital LLC Acquires 17,866 Shares of Tempus AI, Inc. $TEM

Renaissance Capital LLC boosted its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 26.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,166 shares of the company’s stock after purchasing an additional 17,866 shares during the quarter. Tempus AI comprises approximately 3.8% of Renaissance Capital LLC’s portfolio, making the stock its 9th biggest position. Renaissance Capital LLC’s holdings in Tempus AI were worth $6,793,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cranbrook Wealth Management LLC purchased a new position in shares of Tempus AI during the third quarter worth approximately $25,000. Concord Wealth Partners boosted its stake in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the period. GAMMA Investing LLC purchased a new position in Tempus AI during the 3rd quarter worth $28,000. Allworth Financial LP increased its stake in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Finally, SouthState Corp boosted its stake in shares of Tempus AI by 3,761.5% during the second quarter. SouthState Corp now owns 502 shares of the company’s stock worth $32,000 after buying an additional 489 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the sale, the chief executive officer directly owned 8,974,783 shares of the company’s stock, valued at approximately $574,296,364.17. This trade represents a 1.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Erik Phelps sold 1,302 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the transaction, the executive vice president owned 89,280 shares in the company, valued at approximately $6,019,257.60. The trade was a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 932,832 shares of company stock valued at $71,324,324. 26.27% of the stock is owned by company insiders.

Tempus AI Stock Down 1.8%

TEM opened at $60.39 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The stock has a market capitalization of $10.74 billion, a P/E ratio of -50.75 and a beta of 4.99. The business has a 50 day simple moving average of $73.96 and a 200-day simple moving average of $73.62.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.Tempus AI’s revenue was up 84.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.46) earnings per share. On average, equities analysts anticipate that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEM has been the topic of a number of research reports. Guggenheim raised their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. BTIG Research lifted their target price on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Morgan Stanley boosted their target price on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Canaccord Genuity Group decreased their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Finally, HC Wainwright dropped their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $84.00.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.